F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

Overview

Journal Mol Imaging Radionucl Ther

Date 2017 Mar 15

PMID 28291004

Citations 2

Authors

Mine Araz

Derya Cayir

Affiliations

Soon will be listed here.

Abstract

Positron emission tomography/computed tomography (PET/CT) with F-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of F-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting.

Citing Articles

Nuclear Imaging Modalities in the Diagnosis and Management of Thyroid Cancer.

Singh N, Hage N, Ramamourthy B, Nagaraju S, Kappagantu K Curr Mol Med. 2023; 24(9):1091-1096.

PMID: 37724677 DOI: 10.2174/1566524023666230915103723.

A Multimodal and Pathological Analysis of a Renal Cell Carcinoma Metastasis to the Thyroid Gland 11 Years Post Nephrectomy.

Geisbush T, Dymon Z, Gabriel M, Yedavalli V J Radiol Case Rep. 2019; 13(4):1-9.

PMID: 31565176 PMC: 6743643. DOI: 10.3941/jrcr.v13i4.3497.

References

Stojadinovic A, Hoos A, Ghossein R, Urist M, Leung D, Spiro R . Hürthle cell carcinoma: a 60-year experience. Ann Surg Oncol. 2002; 9(2):197-203. DOI: 10.1007/BF02557374. View

Marcus C, Whitworth P, Surasi D, Pai S, Subramaniam R . PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014; 202(6):1316-29. DOI: 10.2214/AJR.13.11673. View

Volkan-Salanci B, Ozgen Kiratli P . Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients. Mol Imaging Radionucl Ther. 2015; 24(2):47-59. PMC: 4563170. DOI: 10.4274/mirt.76476. View

Hegerova L, Griebeler M, Reynolds J, Henry M, Gharib H . Metastasis to the thyroid gland: report of a large series from the Mayo Clinic. Am J Clin Oncol. 2013; 38(4):338-42. DOI: 10.1097/COC.0b013e31829d1d09. View

Machens A, Dralle H . Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010; 95(6):2655-63. DOI: 10.1210/jc.2009-2368. View

Treglia G, Bongiovanni M, Paone G, Ceriani L, Giovanella L . Metastatic undifferentiated spindle cell sarcoma of the thyroid gland evaluated by 18F-FDG PET/CT. Clin Nucl Med. 2014; 40(3):e208-10. DOI: 10.1097/RLU.0000000000000552. View

Luster M, Karges W, Zeich K, Pauls S, Verburg F, Dralle H . Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010; 20(5):527-33. DOI: 10.1089/thy.2009.0342. View

Nikiforov Y . Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2005; 15(4):319-27. DOI: 10.1385/ep:15:4:319. View

Diehl M, Risse J, Brandt-Mainz K, Dietlein M, Bohuslavizki K, Matheja P . Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001; 28(11):1671-6. DOI: 10.1007/s002590100614. View

10.

Wang W, Larson S, Fazzari M, Tickoo S, Kolbert K, Sgouros G . Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000; 85(3):1107-13. DOI: 10.1210/jcem.85.3.6458. View

11.

Kim B, Kim S, Kim K, Kim H, Kim S, Kim W . High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med. 2015; 29(8):721-9. PMC: 4661206. DOI: 10.1007/s12149-015-0994-2. View

12.

Archier A, Heimburger C, Guerin C, Morange I, Palazzo F, Henry J . (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2015; 43(6):1027-33. DOI: 10.1007/s00259-015-3227-y. View

13.

De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A . Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma. Ann Nucl Med. 2016; 30(3):234-41. DOI: 10.1007/s12149-015-1056-5. View

14.

Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G . Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol. 2008; 33(4):341-57. View

15.

Pryma D, Schoder H, Gonen M, Robbins R, Larson S, Yeung H . Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006; 47(8):1260-6. View

16.

Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J . Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007; 34(10):1604-9. DOI: 10.1007/s00259-007-0425-2. View

17.

Are C, Hsu J, Ghossein R, Schoder H, Shah J, Shaha A . Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol. 2007; 14(11):3210-5. DOI: 10.1245/s10434-007-9531-4. View

18.

Khan N, Oriuchi N, Higuchi T, Endo K . Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005; 12(4):254-60. DOI: 10.1177/107327480501200408. View

19.

Agrawal K, Weaver J, Ul-Hassan F, Jeannon J, Simo R, Carroll P . Incidence and Significance of Incidental Focal Thyroid Uptake on (18)F-FDG PET Study in a Large Patient Cohort: Retrospective Single-Centre Experience in the United Kingdom. Eur Thyroid J. 2015; 4(2):115-22. PMC: 4521059. DOI: 10.1159/000431319. View

20.

Iagaru A, Masamed R, Singer P, Conti P . Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. Mol Imaging Biol. 2006; 9(2):72-7. DOI: 10.1007/s11307-006-0072-1. View